Navigation Links
Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
Date:6/13/2010

UNION CITY, Calif., June 11 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has received notification from the U.S. Food & Drug Administration (FDA) that the PDUFA date for Questcor's supplemental new drug application (sNDA) to approve Acthar for the treatment of infantile spasms (IS) has been extended to September 11, 2010.  The FDA extended the PDUFA date in order to review information regarding labeling and potential post-approval commitments that they solicited from Questcor. This follows the May 6, 2010 votes by the Advisory Committee to the Division of Peripheral and Central Nervous System Drugs of the FDA which indicated support for approval of this new Acthar indication.  

"We look forward to working with the FDA over the next few months in order to finalize these critical elements," said Don M. Bailey, President and CEO of Questcor.

Investors should note that there can be no assurance that the FDA will approve this sNDA by September 11, 2010, or thereafter.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
2. Trading Halted Today in Questcor Pharmaceuticals Common Stock
3. Questcor to Discuss Results From FDA Panel Meeting
4. Questcor Reports Solid Fourth Quarter Results
5. Mylan Receives Approval for Generic Version of Neurontin® Tablets
6. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
7. Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension
8. Amedica® Receives Patent for Hip Implant Using Monoblock Ceramic Technology
9. The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup
10. PolyGel® Receives SADMERC Approval for L-Code L0627 for New ThermoActive™ Plus Cold & Hot Compression Lumbar Orthosis
11. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017 The Society ... and the Physician-Patient Alliance for Health & Safety ( ... focused on promoting safety and optimized outcomes for patients ... Gross MD, President of SONORIA and Michael Wong ... serve as advisors to their respective organization,s Boards. ...
(Date:1/24/2017)... , January 24, 2017 www.Financialbuzz.com ... growing industries in the United States ... in 2016. In addition, Proposition 64, the California Cannabis Legalization ... 42.87% against on November 8, 2016. This outcome means that ... use and to grow a certain amount of cannabis for ...
(Date:1/24/2017)... 24, 2017 Mezzion has filed a suit ... court alleging that Dr. Reddy,s committed fraud relating to ... Drug Administration (FDA) cGMP practices, and misrepresenting its compliance ... represented to Mezzion that it was compliant with FDA ... The suit also states that Dr. Reddy,s misconduct was ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... The Behavioral ... with an Award of Distinction, recognizing the organization as a top behavioral service ... in the areas of clinical quality, staff satisfaction, and qualifications and consumer satisfaction. ...
(Date:1/24/2017)... , ... January 24, 2017 , ... World Patent Marketing, ... its website invention store . , Retro Patents was co-founded by Craig ... that gives users access to millions of songs, acquired Soundwave from Craig in 2016. ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... United States Environmental Protection Agency (EPA) in its new recommendations of standards ... Innovation Institute has announced. , Cradle to Cradle Certified is recommended at ...
(Date:1/24/2017)... Plains, N.J. (PRWEB) , ... January 24, 2017 , ... ... helping patients for nearly six decades. She joins Dr. Robert V. Scalera, Jr., ... addition to our practice,” said Dr. Scalera, Jr., a general dentist and director of ...
(Date:1/24/2017)... ... January 24, 2017 , ... A fifth-year speaker at the 2017 ... will return to present about the state of the Affordable Care Act (ACA) with ... this year – will be hosted at Disney’s Grand Californian Hotel & Spa from ...
Breaking Medicine News(10 mins):